# Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

> **NCT01754870** · PHASE2 · WITHDRAWN · sponsor: **University of Wisconsin, Madison**

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)

## Interventions

- **DRUG:** Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance

## Key facts

- **NCT ID:** NCT01754870
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-11
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2019-11-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01754870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01754870, "Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01754870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*